Survival Analysis Of Breast Cancer Patients With Different Chemotherapy Regimens After Surgery

Objectives The purpose of this study was to compare breast cancer patients’ survival with different chemotherapy regimens after surgery, and provide a scientific basis for selecting the chemotherapy regimen.Methods Breast cancer patients were selected as subjects in North China University of Science and Technology affiliated hospital from Jan 2004 to Dec 2009. And baseline data including clinical data and chemotherapy regimen’s data were collected and the 5-year survival status was followed-up by 2 graduates through phone and case record. The database was built by excel 2003 and was analyzed by SPSS software. Chemotherapy regimens were divided into anthracycline regimen, anthracycline combined taxane regimen, CMF regimen and other drug regimen. The survival rate, metastasis rate, overall survival and disease-free survival between anthracycline regimen and anthracycline combined taxanes regimen was analyzed by Kaplan-Meier methods. OS and DFS between different chemotherapy regimen was compared by the COX regression model after adjusting age, TNM and so on.Results There was no significance difference in age, BMI, BP, menstrual status, pathological status, recptors, surgical procedures of breast cancer patients between anthracycline regimen and anthracycline combined taxane regimen(P>0.05). But the presence of lymph node metastases and radiotherapy status between the two regimens was statistically difference(P < 0.05). The OS were respectively 57.0±0.8 months and 54.7±1.4 months, the DFS were 52.6±1.3 months and 50.2±1.8 months in two regimens by Kaplan-Meier method. 1 year overall survival rate of anthracycline regimen and anthracycline combined taxanes regimen was 98.3% and 94.2%, the metastasis rate was 1.7% and 4.3% respectively. 3 year overall survival rate between two regimens was 94.9% and 89.9%, the metastasis rate was16.1% and 20.3% respectively. 5 year overall survival rate between two regimens was 86.0% and 81.6%, the metastasis rate was 22.9% and 30.4% respectively. By Log-Rank test showed, there was no significant statistically difference in the overall survival rate and metastasis rate between two chemotherapy regimens(P>0.05). After stratified by the lymph nodes and radiotherapy, there were no significantly different in survival rate and metastasis rate of different chemotherapy regimen. After adjusting variety prognostic factors of breast cancer such as age, BMI, lymph node status by the COX regression model, there was no difference of survival rate between breast cancer patients with different chemotherapy regimens(P=0.235). And stratified by lymph node status and radiotherapy status, there remained no difference after adjusting variety prognostic factors of breast cancer(P>0.05).Conclusions There had no significant difference in 5-year overall survival and diseasefree survival of breast cancer patients between anthracycline regimen and anthracycline combined taxane regimen.